Section 1 of 4Overview
Overview
A synthetic salmon calcitonin medicine with limited, indication-specific FDA uses.
Primary regulatory source
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.
Section 2 of 4Identity and mechanism
Identity and mechanism
Calcitonin receptor activation reduces osteoclast-mediated bone resorption and lowers serum calcium.
PubChem CID 16220016; C145H240N44O48S2; 3431.9 Da.
Section 3 of 4Regulatory label facts
Regulatory label facts
FDA (United States; restricted indication set in current Miacalcin label).
The dose below reproduces a regulator-approved label; it is not a treatment recommendation.
Section 4 of 4Safety boundary
Safety boundary
The label limits use because fracture-reduction efficacy has not been demonstrated and meta-analysis identified a possible increased malignancy risk; hypersensitivity and hypocalcemia also require attention.
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.